{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:59:31Z","timestamp":1792454371074,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014748","name":"Clarendon Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Muscle Res Cell Motil"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent years have seen enormous progress in the field of advanced therapeutics for the progressive muscle wasting disease Duchenne muscular dystrophy (DMD). In particular, four antisense oligonucleotide (ASO) therapies targeting various DMD-causing mutations have achieved FDA approval, marking major milestones in the treatment of this disease. These compounds are designed to induce alternative splicing events that restore the translation reading frame of the dystrophin gene, leading to the generation of internally-deleted, but mostly functional, pseudodystrophin proteins with the potential to compensate for the genetic loss of dystrophin. However, the efficacy of these compounds is very limited, with delivery remaining a key obstacle to effective therapy. There is therefore an urgent need for improved ASO technologies with better efficacy, and with applicability to a wider range of patient mutations. Here we discuss recent developments in ASO therapies for DMD, and future prospects with a focus on ASO chemical modification and bioconjugation strategies.<\/jats:p>","DOI":"10.1007\/s10974-024-09688-2","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:52:11Z","timestamp":1738198331000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"46","author":[{"given":"Katarzyna","family":"Chwalenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-6011","authenticated-orcid":false,"given":"Matthew J. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-7631","authenticated-orcid":false,"given":"Thomas C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"9688_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2020.0845","volume":"30","author":"A Aartsma-Rus","year":"2020","unstructured":"Aartsma-Rus A, Corey DR (2020) The 10th oligonucleotide therapy approved: Golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther 30:67\u201370","journal-title":"Nucleic Acid Ther"},{"key":"9688_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/nat.2018.0756","volume":"29","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Goemans N (2019) A sequel to the Eteplirsen Saga: Eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid Ther 29:13\u201315","journal-title":"Nucleic Acid Ther"},{"key":"9688_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JCT, Fokkema IF et al (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34:135\u2013144","journal-title":"Muscle Nerve"},{"key":"9688_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293\u2013299","journal-title":"Hum Mutat"},{"key":"9688_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R et al (2017) Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther 27:251\u2013259","journal-title":"Nucleic Acid Ther"},{"key":"9688_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","volume":"5","author":"A Amantana","year":"2005","unstructured":"Amantana A, Iversen PL (2005) Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol 5:550\u2013555","journal-title":"Curr Opin Pharmacol"},{"key":"9688_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/hgtb.2012.117","volume":"23","author":"K Anthony","year":"2012","unstructured":"Anthony K, Feng L, Arechavala-Gomeza V et al (2012) Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen. Hum Gene Ther Methods 23:336\u2013345","journal-title":"Hum Gene Ther Methods"},{"key":"9688_CR8","unstructured":"Avidity biosciences reports positive data demonstrating AOC 1044 delivers unprecedented concentrations of PMO in muscle following a single dose in healthy volunteers from phase 1\/2 EXPLORE44TM trial for Duchenne muscular dystrophy Available from: https:\/\/www.prnewswire.com\/news-releases\/avidity-biosciences-reports-positive-data-demonstrating-aoc-1044-delivers-unprecedented-concentrations-of-pmo-in-muscle-following-a-single-dose-in-healthy-volunteers-from-phase-12-explore44-trial-for-duchenne-muscular-dystrophy-302013456.html"},{"key":"9688_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts C, Saleh AF, Arzumanov AA et al (2012) Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids 1:e38","journal-title":"Mol Ther Nucleic Acids"},{"key":"9688_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep08986","author":"CA Betts","year":"2015","unstructured":"Betts CA, Saleh AF, Carr CA et al (2015) Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci Rep. https:\/\/doi.org\/10.1038\/srep08986","journal-title":"Sci Rep"},{"key":"9688_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD Global Database: analysis of more than 7000 Duchenne muscular dystrophy mutations. Hum Mutat 36:395\u2013402","journal-title":"Hum Mutat"},{"key":"9688_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.scr.2014.10.007","volume":"14","author":"L Boldrin","year":"2015","unstructured":"Boldrin L, Zammit PS, Morgan JE (2015) Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Res 14:20","journal-title":"Stem Cell Res"},{"key":"9688_CR13","doi-asserted-by":"publisher","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","volume":"59","author":"W Brad Wan","year":"2016","unstructured":"Brad Wan W, Seth PP (2016) The medicinal chemistry of therapeutic oligonucleotides. J Med Chem 59:9645\u20139667","journal-title":"J Med Chem"},{"key":"9688_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77\u201393","journal-title":"Lancet Neurol"},{"key":"9688_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-023-01657-z","volume":"11","author":"N Cardone","year":"2023","unstructured":"Cardone N, Taglietti V, Baratto S et al (2023) Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells. Acta Neuropathol Commun 11:1\u201311","journal-title":"Acta Neuropathol Commun"},{"key":"9688_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.omtn.2022.08.033","volume":"29","author":"K Chwalenia","year":"2022","unstructured":"Chwalenia K, Oieni J, Zem\u0142a J et al (2022) Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties. Mol Ther Nucleic Acids 29:955\u2013968","journal-title":"Mol Ther Nucleic Acids"},{"key":"9688_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","volume":"378","author":"S Cirak","year":"2011","unstructured":"Cirak S, Arechavala-Gomeza V, Guglieri M et al (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:595\u2013605","journal-title":"Lancet"},{"key":"9688_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/mus.27011","volume":"62","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Niizawa G, Feng J et al (2020a) The CINRG Becker natural history study: baseline characteristics. Muscle Nerve 62:369\u2013376","journal-title":"Muscle Nerve"},{"key":"9688_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM et al (2020b) Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol 77:982\u2013991","journal-title":"JAMA Neurol"},{"key":"9688_CR20","unstructured":"Community letter: update SRP-5051 program|Sarepta therapeutics Available from: https:\/\/www.sarepta.com\/community-letter-update-srp-5051-program"},{"key":"9688_CR21","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","volume":"50","author":"CA Desjardins","year":"2022","unstructured":"Desjardins CA, Yao M, Hall J et al (2022) Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res 50:11401\u201311414","journal-title":"Nucleic Acids Res"},{"key":"9688_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E et al (2020) Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med 9:1\u201324","journal-title":"J Clin Med"},{"key":"9688_CR23","unstructured":"Dyne reports positive phase 1\/2 data for Duchenne agent DYNE-251 Available from: https:\/\/www.neurologylive.com\/view\/dyne-reports-positive-phase-1-2-data-duchenne-agent-dyne-251"},{"key":"9688_CR24","unstructured":"Dyne therapeutics presents data at world muscle society congress highlighting promise of FORCETM platform to address underlying causes of neuromuscular diseases|Dyne Therapeutics, Inc. Available from: https:\/\/investors.dyne-tx.com\/news-releases\/news-release-details\/dyne-therapeutics-presents-data-world-muscle-society-congress"},{"key":"9688_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"SB England","year":"1990","unstructured":"England SB, Nicholson LVB, Johnson MA et al (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343:180\u2013182","journal-title":"Nature"},{"key":"9688_CR26","unstructured":"Entrada therapeutics|Entrada therapeutics reports positive preliminary data in healthy volunteers from phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy Available from: https:\/\/ir.entradatx.com\/news-releases\/news-release-details\/entrada-therapeutics-reports-positive-preliminary-data-healthy"},{"key":"9688_CR27","unstructured":"First clinical trial results of gene therapy (GNT0004) for Duchenne muscular dystrophy presented at international myology (2024) Congress Available from: https:\/\/www.genethon.com\/first-clinical-trial-results-of-gene-therapy-gnt0004-for-duchenne-muscular-dystrophy-presented-at-international-myology-2024-congress\/"},{"key":"9688_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","volume":"28","author":"N Goemans","year":"2018","unstructured":"Goemans N, Mercuri E, Belousova E et al (2018) A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord 28:4\u201315","journal-title":"Neuromuscul Disord"},{"key":"9688_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle A, Griffith G, Babbs A et al (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 21:270\u2013275","journal-title":"Nat Med"},{"key":"9688_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.omtn.2022.10.010","volume":"30","author":"B Hanson","year":"2022","unstructured":"Hanson B, Stenler S, Ahlskog N et al (2022) Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin\/utrophin double-knockout mouse model of DMD. Mol Ther Nucleic Acids 30:379\u2013397","journal-title":"Mol Ther Nucleic Acids"},{"key":"9688_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A (2020) Golodirsen: first approval. Drugs 80:329\u2013333","journal-title":"Drugs"},{"key":"9688_CR32","doi-asserted-by":"crossref","unstructured":"High-dose AAV gene therapy deaths 2020 High-dose AAV gene therapy deaths (2020) Nat Biotechnol 38: 910.","DOI":"10.1038\/s41587-020-0642-9"},{"key":"9688_CR33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928","journal-title":"Cell"},{"key":"9688_CR34","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Delandistrogene moxeparvovec: first approval. Drugs 83:1323\u20131329","journal-title":"Drugs"},{"key":"9688_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.292.5518.929","volume":"292","author":"T Ideker","year":"2001","unstructured":"Ideker T, Thorsson V, Ranish JA et al (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292:929\u2013934","journal-title":"Science"},{"key":"9688_CR36","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cimb43030090","volume":"43","author":"K Ito","year":"2021","unstructured":"Ito K, Takakusa H, Kakuta M et al (2021) Renadirsen, a Novel 2\u2019OMeRNA\/ENA\u00ae Chimera antisense oligonucleotide, induces robust exon 45 skipping for dystrophin in vivo. Curr Issues Mol Biol 43:1267\u20131281","journal-title":"Curr Issues Mol Biol"},{"key":"9688_CR37","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1093\/nar\/gkac018","volume":"50","author":"P Kandasamy","year":"2022","unstructured":"Kandasamy P, McClorey G, Shimizu M et al (2022a) Control of backbone chemistry and chirality boost oligonucleotide splice switching activity. Nucleic Acids Res 50:5443","journal-title":"Nucleic Acids Res"},{"key":"9688_CR38","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1093\/nar\/gkac037","volume":"50","author":"P Kandasamy","year":"2022","unstructured":"Kandasamy P, Liu Y, Aduda V et al (2022b) Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS. Nucleic Acids Res 50:5401\u20135423","journal-title":"Nucleic Acids Res"},{"key":"9688_CR39","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali M, Arechavala-Gomeza V, Feng L et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918","journal-title":"Lancet Neurol"},{"key":"9688_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713","author":"H Komaki","year":"2018","unstructured":"Komaki H, Nagata T, Saito T et al (2018) Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan0713","journal-title":"Sci Transl Med"},{"key":"9688_CR41","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.nmd.2023.07.025","volume":"33","author":"J Larkindale","year":"2023","unstructured":"Larkindale J, Lonkar P, Goyal J et al (2023) P44 phase 1 study of PGN-EDO51 demonstrates tolerability, delivery and high levels of exon skipping for treatment of Duchenne muscular dystrophy (DMD). Neuromuscul Disord 33:S69","journal-title":"Neuromuscul Disord"},{"key":"9688_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A (2024) Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med 4:1\u201311","journal-title":"Commun Med"},{"key":"9688_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533","journal-title":"Drug Des Devel Ther"},{"key":"9688_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C, Amoasii L, Mireault AA et al (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400\u2013403","journal-title":"Science"},{"key":"9688_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.735912","author":"T Markati","year":"2021","unstructured":"Markati T, De Waele L, Schara-Schmidt U et al (2021) Lessons learned from discontinued clinical developments in Duchenne muscular dystrophy. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.735912","journal-title":"Front Pharmacol"},{"key":"9688_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/biomedicines6020051","volume":"6","author":"G McClorey","year":"2018","unstructured":"McClorey G, Banerjee S (2018) Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics. Biomedicines 6:51","journal-title":"Biomedicines"},{"key":"9688_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM et al (2023) Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2023.1167762","journal-title":"Front Cell Dev Biol"},{"key":"9688_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mus.880120511","volume":"12","author":"JE Morgan","year":"1989","unstructured":"Morgan JE, Coulton GR, Partridge TA (1989) Mdx muscle grafts retain the mdx phenotype in normal hosts. Muscle Nerve 12:401\u2013409","journal-title":"Muscle Nerve"},{"key":"9688_CR49","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1083\/jcb.111.6.2437","volume":"111","author":"JE Morgan","year":"1990","unstructured":"Morgan JE, Hoffman EP, Partridge TA (1990) Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111:2437","journal-title":"J Cell Biol"},{"key":"9688_CR50","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1006\/dbio.1994.1103","volume":"162","author":"JE Morgan","year":"1994","unstructured":"Morgan JE, Beauchamp JR, Pagel CN et al (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162:486\u2013498","journal-title":"Dev Biol"},{"key":"9688_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206324120","volume":"120","author":"A Morin","year":"2023","unstructured":"Morin A, Stantzou A, Petrova ON et al (2023) Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle. Proc Natl Acad Sci USA 120:e2206324120","journal-title":"Proc Natl Acad Sci USA"},{"key":"9688_CR52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731\u2013740","journal-title":"Lancet Neurol"},{"key":"9688_CR53","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230107","author":"S Nicolau","year":"2024","unstructured":"Nicolau S, Malhotra J, Kaler M et al (2024) Increase in full-length dystrophin by exon skipping in Duchenne muscular dystrophy patients with single exon duplications: an open-label study. J Neuromuscul Dis. https:\/\/doi.org\/10.3233\/JND-230107","journal-title":"J Neuromuscul Dis"},{"key":"9688_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/337176a0","volume":"337","author":"TA Partridge","year":"1989","unstructured":"Partridge TA, Morgan JE, Coulton GR et al (1989) Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337:176\u2013179","journal-title":"Nature"},{"key":"9688_CR55","first-page":"121","volume":"31","author":"L Passamano","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A et al (2012) Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myologica 31:121","journal-title":"Acta Myologica"},{"key":"9688_CR56","unstructured":"PepGen reports positive data from phase 1 trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy|PepGen Available from: https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-reports-positive-data-phase-1-trial-pgn-edo51-treatment"},{"key":"9688_CR57","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH et al (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90:3710","journal-title":"Proc Natl Acad Sci USA"},{"key":"9688_CR58","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1093\/hmg\/ddv381","volume":"24","author":"TC Roberts","year":"2015","unstructured":"Roberts TC, Johansson HJ, McClorey G et al (2015) Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet 24:6756","journal-title":"Hum Mol Genet"},{"key":"9688_CR59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discovery 19:673\u2013694","journal-title":"Nat Rev Drug Discovery"},{"key":"9688_CR60","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJA, Davies KE (2023) Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov 22:917\u2013934","journal-title":"Nat Rev Drug Discov"},{"key":"9688_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","volume":"2587","author":"RR Roshmi","year":"2023","unstructured":"Roshmi RR, Yokota T (2023) Viltolarsen: from preclinical studies to FDA approval. Methods Mol Biol 2587:31\u201341","journal-title":"Methods Mol Biol"},{"key":"9688_CR62","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.nmd.2023.07.156","volume":"33","author":"R Rossi","year":"2023","unstructured":"Rossi R, Singh S, Torelli S et al (2023) P29 DMD transcript imbalance and nuclear trafficking evaluation in muscle biopsies from baseline and golodirsen treated 4053\u2013101 clinical trial patients. Neuromuscul Disord 33:S104","journal-title":"Neuromuscul Disord"},{"key":"9688_CR63","unstructured":"Sarepta therapeutics announces positive data from part B of MOMENTUM, a phase 2 study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51|Sarepta Therapeutics, Inc. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-positive-data-part-b-momentum"},{"key":"9688_CR64","unstructured":"Sarepta therapeutics announces third quarter 2024 financial results and recent corporate developments|Sarepta Therapeutics, Inc. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-third-quarter-2024-financial"},{"key":"9688_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V et al (2022) Long-term safety and efficacy data of Golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther 32:29","journal-title":"Nucleic Acid Ther"},{"key":"9688_CR66","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M (2021) Casimersen: first approval. Drugs 81:875\u2013879","journal-title":"Drugs"},{"key":"9688_CR67","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75:285","journal-title":"Proc Natl Acad Sci USA"},{"key":"9688_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187\u2013195","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"9688_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo SM, Salhany RM, Deighton A et al (2021) The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis 16:1\u201313","journal-title":"Orphanet J Rare Dis"},{"key":"9688_CR70","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JKW et al (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351:407\u2013411","journal-title":"Science"},{"key":"9688_CR71","volume-title":"Becker muscular dystrophy","author":"PK Thada","year":"2023","unstructured":"Thada PK, Bhandari J, Umapathi KK (2023) Becker muscular dystrophy. StatPearls, St. Petersburg"},{"key":"9688_CR72","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.nmd.2023.07.149","volume":"33","author":"M Tillinger","year":"2023","unstructured":"Tillinger M, Lake S, Servais L et al (2023) P22 WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses. Neuromuscul Disord 33:S102","journal-title":"Neuromuscul Disord"},{"key":"9688_CR73","doi-asserted-by":"publisher","first-page":"e19189","DOI":"10.1371\/journal.pone.0019189","volume":"6","author":"JM Tinsley","year":"2011","unstructured":"Tinsley JM, Fairclough RJ, Storer R et al (2011) Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE 6:e19189","journal-title":"PLoS ONE"},{"key":"9688_CR74","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","volume":"45","author":"MK Tsoumpra","year":"2019","unstructured":"Tsoumpra MK, Fukumoto S, Matsumoto T et al (2019) Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 45:630\u2013645","journal-title":"EBioMedicine"},{"key":"9688_CR75","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/jcsm.12506","volume":"11","author":"TLE van Westering","year":"2020","unstructured":"van Westering TLE, Lomonosova Y, Coenen-Stass AML et al (2020) Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. J Cachexia Sarcopenia Muscle 11:578\u2013593","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"9688_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3988\/jcn.2017.13.1.91","volume":"13","author":"S Vengalil","year":"2017","unstructured":"Vengalil S, Preethish-Kumar V, Polavarapu K et al (2017) Duchenne muscular dystrophy and Becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: genotype-phenotype correlation in a large cohort. J Clin Neurol 13:91\u201397","journal-title":"J Clin Neurol"},{"key":"9688_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02801-4","author":"LY Vincik","year":"2024","unstructured":"Vincik LY, Dautel AD, Staples AA et al (2024) Evolving role of Viltolarsen for treatment of Duchenne muscular dystrophy. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-024-02801-4","journal-title":"Adv Ther"},{"key":"9688_CR78","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1016\/j.nmd.2019.06.489","volume":"29","author":"K Wagner","year":"2019","unstructured":"Wagner K, Cripe L, Eagle M et al (2019) EP.83Design of a Phase 2\/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping. Neuromuscul Disord 29:S176\u2013S177","journal-title":"Neuromuscul Disord"},{"key":"9688_CR79","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/BF00309688","volume":"175","author":"DJ Watt","year":"1987","unstructured":"Watt DJ, Morgan JE, Clifford MA et al (1987) The movement of muscle precursor cells between adjacent regenerating muscles in the mouse. Anat Embryol (Berl) 175:527\u2013536","journal-title":"Anat Embryol (Berl)"},{"key":"9688_CR80","unstructured":"Wave life sciences announces positive interim data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in boys with Duchenne muscular dystrophy amenable to exon 53 skipping - wave life sciences Available from: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-positive-interim-data-forward-53"},{"key":"9688_CR81","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/gt.2009.120","volume":"17","author":"B Wu","year":"2010","unstructured":"Wu B, Lu P, Benrashid E et al (2010) Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17:132\u2013140","journal-title":"Gene Ther"},{"key":"9688_CR82","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/mt.2011.79","volume":"19","author":"H Yin","year":"2011","unstructured":"Yin H, Saleh AF, Betts C et al (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19:1295\u20131303","journal-title":"Mol Ther"},{"key":"9688_CR83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ana.26409","volume":"92","author":"F Zarrouki","year":"2022","unstructured":"Zarrouki F, Relizani K, Bizot F et al (2022) Partial restoration of brain dystrophin and behavioral deficits by exon skipping in the muscular dystrophy X-linked (mdx) mouse. Ann Neurol 92:213\u2013229","journal-title":"Ann Neurol"}],"container-title":["Journal of Muscle Research and Cell Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10974-024-09688-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10974-024-09688-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10974-024-09688-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:01:26Z","timestamp":1766149286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10974-024-09688-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9688"],"URL":"https:\/\/doi.org\/10.1007\/s10974-024-09688-2","relation":{},"ISSN":["0142-4319","1573-2657"],"issn-type":[{"value":"0142-4319","type":"print"},{"value":"1573-2657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.J.A.W. is a founder, shareholder, and consultant for PepGen Ltd, a biotech company that aims to commercialise PPMO technology. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}